-
Je něco špatně v tomto záznamu ?
Change in ploidy status from hyperdiploid to near-tetraploid in multiple myeloma associated with bortezomib/lenalidomide resistance
L. Pavlistova, Z. Zemanova, I. Sarova, H. Lhotska, A. Berkova, I. Spicka, K. Michalova,
Cancer genetics.
2014 ;
207 (7-8) :
326-31.
Jazyk angličtina Země Spojené státy americké
Typ dokumentu kazuistiky, časopisecké články, práce podpořená grantem
Perzistentní odkaz
https://www.medvik.cz/link/bmc15014087
- MeSH
- chemorezistence genetika MeSH
- chromozomální aberace MeSH
- hybridizace in situ fluorescenční MeSH
- imunoglobuliny genetika MeSH
- kyseliny boronové aplikace a dávkování MeSH
- lidé středního věku MeSH
- lidé MeSH
- lokální recidiva nádoru farmakoterapie genetika patologie MeSH
- mnohočetný myelom farmakoterapie genetika patologie MeSH
- ploidie * MeSH
- prognóza MeSH
- protokoly antitumorózní kombinované chemoterapie terapeutické užití MeSH
- pyraziny aplikace a dávkování MeSH
- srovnávací genomová hybridizace MeSH
- thalidomid aplikace a dávkování analogy a deriváty MeSH
- Check Tag
- lidé středního věku MeSH
- lidé MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- kazuistiky MeSH
- práce podpořená grantem MeSH
Ploidy is an important prognostic factor in the risk stratification of multiple myeloma (MM) patients. Patients with MM can be divided into two groups according to the modal number of chromosomes: nonhyperdiploid (NH-MM) and hyperdiploid (H-MM), which has a more favorable outcome. The two ploidy groups represent two different oncogenetic pathways determined at the premalignant stage. The ploidy subtype also persists during the course of the disease, even during progression after the therapy, with only very rare cases of ploidy conversion. The clinical significance of ploidy conversion and its relation to drug resistance have been previously discussed. Here, we describe a female MM patient with a rare change in her ploidy status from H-MM to NH-MM, detected by cytogenetic and molecular cytogenetic examinations of consecutive bone marrow aspirates. We hypothesize that ploidy conversion (from H-MM to NH-MM) is associated with disease progression and acquired resistance to bortezomib/lenalidomide therapy.
- 000
- 00000naa a2200000 a 4500
- 001
- bmc15014087
- 003
- CZ-PrNML
- 005
- 20150424103848.0
- 007
- ta
- 008
- 150420s2014 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.cancergen.2014.06.027 $2 doi
- 035 __
- $a (PubMed)25178944
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Pavlistova, Lenka $u Center of Oncocytogenetics, Institute of Medical Biochemistry and Laboratory Diagnostics, General University Hospital, First Faculty of Medicine of Charles University, Prague, Czech Republic. Electronic address: lenka.pavlistova@seznam.cz.
- 245 10
- $a Change in ploidy status from hyperdiploid to near-tetraploid in multiple myeloma associated with bortezomib/lenalidomide resistance / $c L. Pavlistova, Z. Zemanova, I. Sarova, H. Lhotska, A. Berkova, I. Spicka, K. Michalova,
- 520 9_
- $a Ploidy is an important prognostic factor in the risk stratification of multiple myeloma (MM) patients. Patients with MM can be divided into two groups according to the modal number of chromosomes: nonhyperdiploid (NH-MM) and hyperdiploid (H-MM), which has a more favorable outcome. The two ploidy groups represent two different oncogenetic pathways determined at the premalignant stage. The ploidy subtype also persists during the course of the disease, even during progression after the therapy, with only very rare cases of ploidy conversion. The clinical significance of ploidy conversion and its relation to drug resistance have been previously discussed. Here, we describe a female MM patient with a rare change in her ploidy status from H-MM to NH-MM, detected by cytogenetic and molecular cytogenetic examinations of consecutive bone marrow aspirates. We hypothesize that ploidy conversion (from H-MM to NH-MM) is associated with disease progression and acquired resistance to bortezomib/lenalidomide therapy.
- 650 _2
- $a protokoly antitumorózní kombinované chemoterapie $x terapeutické užití $7 D000971
- 650 _2
- $a kyseliny boronové $x aplikace a dávkování $7 D001897
- 650 _2
- $a chromozomální aberace $7 D002869
- 650 _2
- $a srovnávací genomová hybridizace $7 D055028
- 650 _2
- $a chemorezistence $x genetika $7 D019008
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a imunoglobuliny $x genetika $7 D007136
- 650 _2
- $a hybridizace in situ fluorescenční $7 D017404
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a mnohočetný myelom $x farmakoterapie $x genetika $x patologie $7 D009101
- 650 _2
- $a lokální recidiva nádoru $x farmakoterapie $x genetika $x patologie $7 D009364
- 650 12
- $a ploidie $7 D011003
- 650 _2
- $a prognóza $7 D011379
- 650 _2
- $a pyraziny $x aplikace a dávkování $7 D011719
- 650 _2
- $a thalidomid $x aplikace a dávkování $x analogy a deriváty $7 D013792
- 655 _2
- $a kazuistiky $7 D002363
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Zemanova, Zuzana $u Center of Oncocytogenetics, Institute of Medical Biochemistry and Laboratory Diagnostics, General University Hospital, First Faculty of Medicine of Charles University, Prague, Czech Republic.
- 700 1_
- $a Sarova, Iveta $u Center of Oncocytogenetics, Institute of Medical Biochemistry and Laboratory Diagnostics, General University Hospital, First Faculty of Medicine of Charles University, Prague, Czech Republic; Department of Cytogenetics, Institute of Hematology and Blood Transfusion, Prague, Czech Republic.
- 700 1_
- $a Lhotska, Halka $u Center of Oncocytogenetics, Institute of Medical Biochemistry and Laboratory Diagnostics, General University Hospital, First Faculty of Medicine of Charles University, Prague, Czech Republic.
- 700 1_
- $a Berkova, Adela $u Center of Oncocytogenetics, Institute of Medical Biochemistry and Laboratory Diagnostics, General University Hospital, First Faculty of Medicine of Charles University, Prague, Czech Republic.
- 700 1_
- $a Spicka, Ivan $u First Medical Department, General University Hospital, First Faculty of Medicine of Charles University, Prague, Czech Republic.
- 700 1_
- $a Michalova, Kyra $u Center of Oncocytogenetics, Institute of Medical Biochemistry and Laboratory Diagnostics, General University Hospital, First Faculty of Medicine of Charles University, Prague, Czech Republic; Department of Cytogenetics, Institute of Hematology and Blood Transfusion, Prague, Czech Republic.
- 773 0_
- $w MED00180193 $t Cancer genetics $x 2210-7762 $g Roč. 207, č. 7-8 (2014), s. 326-31
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/25178944 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20150420 $b ABA008
- 991 __
- $a 20150424104149 $b ABA008
- 999 __
- $a ok $b bmc $g 1071668 $s 896965
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2014 $b 207 $c 7-8 $d 326-31 $i 2210-7762 $m Cancer genetics $n Cancer Genet $x MED00180193
- LZP __
- $a Pubmed-20150420
